|1.||Serruys, Patrick W: 64 articles (02/2015 - 06/2002)|
|2.||Kwiatkowski, David J: 38 articles (12/2015 - 10/2002)|
|3.||Leon, Martin B: 38 articles (03/2015 - 10/2003)|
|4.||Kastrati, Adnan: 30 articles (08/2015 - 08/2004)|
|5.||Blagosklonny, Mikhail V: 28 articles (04/2015 - 09/2006)|
|6.||Moses, Jeffrey W: 28 articles (01/2010 - 10/2003)|
|7.||Schömig, Albert: 27 articles (11/2013 - 04/2004)|
|8.||Valgimigli, Marco: 26 articles (06/2015 - 05/2004)|
|9.||Park, Seung-Jung: 24 articles (05/2015 - 02/2005)|
|10.||Campistol, Josep M: 24 articles (09/2014 - 01/2004)|
04/01/2009 - "Rapamycin inhibition of cell proliferation, the cell cycle and mTOR signaling, including p70S6 and S6RP phosphorylation, was most effective in benign (MCF10A) and premalignant (MCF10AT; MCF10ATG3B) human breast epithelial cells, relative to MCF10CA1a tumor cells. "
01/22/2008 - "Tumor cell proliferation (measured by Ki-67 staining) was dramatically reduced in seven of 14 patients after 1 wk of rapamycin treatment and was associated with the magnitude of mTOR inhibition (p = 0.0047, Fisher exact test) but not the intratumoral rapamycin concentration. "
06/01/2010 - "Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells."
06/01/1983 - "A new drug (rapamycin) being investigated by the NCI was found to be very effective against the U-251 tumor. "
10/13/2015 - "Mice harboring subcutaneous gallbladder tumors, treated with WYE-354 or rapamycin, exhibited a significant reduction in tumor mass. "
|2.||Renal Cell Carcinoma (Grawitz Tumor)
04/01/2014 - "Inhibitors of the mammalian target of rapamycin (mTOR) have improved the treatment of renal cell carcinoma (RCC). "
01/01/2010 - "This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. "
12/01/2009 - "Clinical trials have validated the importance of mammalian target of rapamycin (mTOR) as a therapeutic target in patients with advanced renal cell carcinoma (RCC). "
08/15/2009 - "Clinical trials have validated the importance of mammalian target of rapamycin (mTOR) as a targeted mechanism in the treatment of renal cell carcinoma (RCC). "
08/01/2008 - "In a randomised controlled trial of advanced renal cell carcinoma patients, targeted therapy to mTOR by means of rapamycin analogues has been shown to significantly improve survival. "
12/01/2012 - "We propose that rapamycin is a novel and clinically relevant pharmacological strategy to target STAT3 activation for treatment of myocardial infarction."
09/01/2008 - "However, the incidence of myocardial infarct may be, slightly but significantly, reduced with sirolimus DES. "
05/15/2007 - "(Sirolimus Eluting Stenting in Acute Myocardial Infarction; http://www.clinicaltrials.gov/ct/show/NCT00288210; NCT00288210)."
01/01/1995 - "Focal myocardial infarction was observed in three of five rats with Rapamycin given at 1.5 mg/kg/day and two of 22 rats with 1.0 mg/kg/day. "
03/08/2007 - "There was a significant reduction in the combined risk of death, myocardial infarction, or reintervention (hazard ratio, 0.43; 95% CI, 0.34 to 0.54) associated with the use of sirolimus-eluting stents. "
04/01/2011 - "The NEVO SES with focal release of sirolimus from reservoirs achieved significantly greater and more consistent suppression of neointimal hyperplasia than the surface-coated TAXUS Liberté PES. "
06/01/2003 - "Neointimal hyperplasia is refractory to conventional immunosuppression although newer agents, such as rapamycin, have shown considerable promise in controlling it. "
08/01/2010 - "In either case, mice lacking Gab2 or treated with rapamycin showed attenuated myeloid hyperplasia and modestly improved survival, but the effects were not cytotoxic and were reversible. "
06/01/2005 - "To evaluate the efficacy of limited short-term systemic administration of rapamycin to prevent neointimal intimal hyperplasia (NIH) in a double-injury rat model of restenosis. "
05/10/2012 - "A perivascular system releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term study."
|5.||Tuberous Sclerosis (Bourneville's Disease)
07/01/2015 - "Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex."
07/01/2015 - "Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future."
09/01/2012 - "Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin."
05/21/2008 - "Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function."
03/01/2005 - "Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models."
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Transplantation (Transplant Recipients)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Homologous Transplantation (Allograft)